Trial
NCT03590652
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of California, San Diego
Collaborators
Celgene; Takeda; Janssen, LP
Condition
Relapsed/Refractory Multiple Myeloma
Intervention
Ixazomib
Why stopped
The trial met its primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-21